- Home
- CUE vs TLSA Comparison
CUE vs TLSA Comparison
Compare CUE & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- TLSA
- Stock Information
- Founded
- CUE 2014
- TLSA 2013
- Country
- CUE United States
- TLSA United Kingdom
- Employees
- CUE N/A
- TLSA N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- TLSA Health Care
- Exchange
- CUE Nasdaq
- TLSA Nasdaq
- Market Cap
- CUE 59.5M
- TLSA 187.0M
- IPO Year
- CUE 2018
- TLSA 2000
- Fundamental
- Price
- CUE $0.73
- TLSA $1.78
- Analyst Decision
- CUE Strong Buy
- TLSA
- Analyst Count
- CUE 2
- TLSA 0
- Target Price
- CUE $3.00
- TLSA N/A
- AVG Volume (30 Days)
- CUE 132.9K
- TLSA 330.7K
- Earning Date
- CUE 11-13-2025
- TLSA 05-06-2025
- Dividend Yield
- CUE N/A
- TLSA N/A
- EPS Growth
- CUE N/A
- TLSA N/A
- EPS
- CUE N/A
- TLSA N/A
- Revenue
- CUE $8,286,000.00
- TLSA N/A
- Revenue This Year
- CUE N/A
- TLSA N/A
- Revenue Next Year
- CUE $13.27
- TLSA N/A
- P/E Ratio
- CUE N/A
- TLSA N/A
- Revenue Growth
- CUE N/A
- TLSA N/A
- 52 Week Low
- CUE $0.45
- TLSA $0.63
- 52 Week High
- CUE $1.99
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- CUE 37.43
- TLSA 49.08
- Support Level
- CUE $0.71
- TLSA $1.63
- Resistance Level
- CUE $0.78
- TLSA $1.88
- Average True Range (ATR)
- CUE 0.03
- TLSA 0.16
- MACD
- CUE -0.01
- TLSA -0.00
- Stochastic Oscillator
- CUE 20.10
- TLSA 69.23
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.